Compounds > 1-octyl-3-methylimidazolium hexafluorophosphate
Page last updated: 2024-11-09

1-octyl-3-methylimidazolium hexafluorophosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-octyl-3-methylimidazolium hexafluorophosphate: is a nonaqueous ionic liquid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2734243
CHEMBL ID595682
SCHEMBL ID20582156
SCHEMBL ID22639041
MeSH IDM0414470

Synonyms (35)

Synonym
1-methyl-3-octylimidazolium hexafluorophosphate, >=95.0%
M2063
304680-36-2
1-methyl-3-n-octylimidazolium hexafluorophosphate
CHEMBL595682
nsc-747265
1-methyl-3-octylimidazolium hexafluorophosphate
NCGC00248974-01
cas-304680-36-2
tox21_200768
NCGC00258322-01
dtxsid5047952 ,
dtxcid1027928
3-methyl-1-octylimidazolium hexafluorophosphate
1-octyl-3-methylimidazolium hexafluorophosphate
AKOS015898232
Q-102685
1-methyl-3-n-octylimidazoliumhexafluorophosphate
AKOS025402722
mfcd03427617
1-methyl-3-octyl-imidazolium hexafluorophosphate
1-methyl-3-octyl-1h-imidazol-3-ium; hexafluoro-??-phosphanuide
AS-71709
3-methyl-1-octyl-3-imidazolium hexafluorophosphate(v)
SCHEMBL20582156
1-methyl-3-octylimidazol-1-ium;hexafluorophosphate
SY039371
AC1798
1h-imidazolium, 1-methyl-3-octyl-, hexafluorophosphate(1-) (1:1)
1-n-octyl-3-methylimidazolium hexafluorophosphate
A876182
SCHEMBL22639041
3-methyl-1-octylimidazolium hexafluorophosphate [omim]pf6
CS-W011905
1-octyl-3-methylimidazoliumhexafluorophosphate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Specifically, exposure of the algae Scenedesmus rubescens, crustaceans Thamnocephalus platyurus and Artemia franciscana, rotifers Brachionus calyciflorus and Brachionus plicatilis and bivalve Mytilus galloprovincialis to different concentrations of [bmim][BF4], [omim][BF4] and/or a binary mixture of [bmim][BF4]-[omim][BF4] (1:1) with or without acetone (carrier solvent), revealed that solvent can differentially mediate ILs' toxic profile."( Toxicity of two imidazolium ionic liquids, [bmim][BF4] and [omim][BF4], to standard aquatic test organisms: Role of acetone in the induced toxicity.
Dailianis, S; Tsarpali, V, 2015)		0.42
"In the present study, the toxic effects of 1-octyl-3-methylimidazolium chloride ([Omim]Cl), 1-octyl-3-methylimidazolium bromide ([Omim]Br) and 1-octyl-3-methylimidazolium tetrafluoroborate ([Omim]BF4) in soil on Vicia faba (V."( Biochemical toxicity and DNA damage of imidazolium-based ionic liquid with different anions in soil on Vicia faba seedlings.
Liu, T; Sun, X; Wang, J; Zhang, C; Zhang, J; Zhu, L, 2015)		0.42
"In the present study, the toxic effects of 1-octyl-3-methylimidazolium chloride ([Omim]Cl) and 1-octyl-3-methylimidazolium tetrafluoroborate ([Omim]BF4) on the zebrafish livers were studied at 0, 5, 10, 20, and 40 mg L(-1) on the 7th and 14th days."( Assessing toxic effects of [Omim]Cl and [Omim]BF4 in zebrafish adults using a biomarker approach.
Guo, Y; Liu, T; Wang, J; Zhang, C; Zhang, J; Zhu, L, 2016)		0.43

Dosage Studied

ExcerptRelevanceReference
" However, the toxic effects of these substances were enhanced as dosing concentrations and exposure times were increased."( Assessing toxic effects of [Omim]Cl and [Omim]BF4 in zebrafish adults using a biomarker approach.
Guo, Y; Liu, T; Wang, J; Zhang, C; Zhang, J; Zhu, L, 2016)		0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency56.03590.002541.796015,848.9004AID1347395; AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency34.95660.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency0.16160.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency8.02950.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency23.20900.001022.650876.6163AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency7.83950.000214.376460.0339AID720692
retinoid X nuclear receptor alphaHomo sapiens (human)Potency15.64190.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.75030.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency17.40430.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency19.48920.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency55.03720.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency44.98630.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency9.42560.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency7.77420.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency10.98140.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency7.77420.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency14.37620.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency13.82470.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (141)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (59)

Assay IDTitleYearJournalArticle
AID455636Anticancer activity against human SNB75 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455662Anticancer activity against human MCF7 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455634Anticancer activity against human SF539 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455667Anticancer activity against human BT549 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455614Anticancer activity against human RPMI8266 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455668Anticancer activity against human T47D cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455648Anticancer activity against human OVCAR4 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455649Anticancer activity against human OVCAR5 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455666Anticancer activity against human MDA-MB-435 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455618Anticancer activity against human HOP62 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455658Anticancer activity against human TK10 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455627Anticancer activity against human HCT116 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455638Anticancer activity against human LOXIMVI cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455613Anticancer activity against human MOLT4 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455620Anticancer activity against human NCI-H226 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455637Anticancer activity against human U251 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455656Anticancer activity against human RXF393 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455642Anticancer activity against human SK-MEL-28 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455623Anticancer activity against human NCI-H460 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455663Anticancer activity against human NCI/ADR-RES cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455664Anticancer activity against human MDA-MB-231 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455647Anticancer activity against human OVCAR-3 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455619Anticancer activity against human HOP92 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455653Anticancer activity against human A498 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455622Anticancer activity against human NCI-H322M cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455379Anticancer activity against human CCRF-CEM cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455629Anticancer activity against human HT-29 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455651Anticancer activity against human SKOV3 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455655Anticancer activity against human Caki1 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455628Anticancer activity against human HCT15 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455646Anticancer activity against human IGROV1 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455645Anticancer activity against human UACC62 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455669Anticancer activity against human MDA-MB-468 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455641Anticancer activity against human SK-MEL-2 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455644Anticancer activity against human UACC257 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455630Anticancer activity against human KM12 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455624Anticancer activity against human NCI-H522 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455643Anticancer activity against human SK-MEL-5 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455660Anticancer activity against human PC3 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455657Anticancer activity against human SN12C cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455615Anticancer activity against human SR cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455611Anticancer activity against human HL-60(TB) cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455632Anticancer activity against human SF268 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455650Anticancer activity against human OVCAR8 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455626Anticancer activity against human HCC2998 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455640Anticancer activity against human M14 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455631Anticancer activity against human SW620 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455654Anticancer activity against human ACHN cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455621Anticancer activity against human NCI-H23 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455661Anticancer activity against human DU145 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455639Anticancer activity against human MALME-3M cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455665Anticancer activity against human Hs 578T cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455616Anticancer activity against human A549 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455659Anticancer activity against human UO31 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455625Anticancer activity against human COLO205 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455652Anticancer activity against human 786-0 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455635Anticancer activity against human SNB19 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455612Anticancer activity against human K562 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
AID455633Anticancer activity against human SF295 cells assessed cell growth at 10 uM after 48 hrs by sulforhodamine B assay relative to control2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (32.43)29.6817
2010's22 (59.46)24.3611
2020's3 (8.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.22 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetone
methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).		2.1110ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
bromide
Bromides: Salts of hydrobromic acid, HBr, with the bromine atom in the 1- oxidation state. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)		2.1710halide anion;
monoatomic bromine
methane
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed). methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).		2.0310alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		2.1710halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
octane
Octanes: Eight-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives.. octane : A straight chain alkane composed of 8 carbon atoms.		2.5220alkanexenobiotic
methanol
Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.		2.110alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
naphthalene
[no description available]		2.0510naphthalenes;
ortho-fused bicyclic arene		apoptosis inhibitor;
carcinogenic agent;
environmental contaminant;
mouse metabolite;
plant metabolite;
volatile oil component
1-octanol
1-Octanol: A colorless, slightly viscous liquid used as a defoaming or wetting agent. It is also used as a solvent for protective coatings, waxes, and oils, and as a raw material for plasticizers. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed). octan-1-ol : An octanol carrying the hydroxy group at position 1.		2.0610octanol;
primary alcohol		antifungal agent;
bacterial metabolite;
fuel additive;
kairomone;
plant metabolite
parathion
[no description available]		2.0510C-nitro compound;
organic thiophosphate;
organothiophosphate insecticide		acaricide;
agrochemical;
avicide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
mouse metabolite
1-propanol
1-Propanol: A colorless liquid made by oxidation of aliphatic hydrocarbons that is used as a solvent and chemical intermediate.. propan-1-ol : The parent member of the class of propan-1-ols that is propane in which a hydrogen of one of the methyl groups is replaced by a hydroxy group.		210propan-1-ols;
short-chain primary fatty alcohol		metabolite;
protic solvent
4-nonylphenol
4-nonylphenol: structure in first source; see also record for nonylphenol. 4-nonylphenol : A member of the class of phenols that is phenol which is para-substituted with a nonyl group.		2.0610phenolsenvironmental contaminant
carbamazepine
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.		2.2510dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
chlorpyrifos
Chlorpyrifos: An organothiophosphate cholinesterase inhibitor that is used as an insecticide and as an acaricide.. chlorpyrifos : An organic thiophosphate that is O,O-diethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.		2.0510chloropyridine;
organic thiophosphate		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
environmental contaminant;
insecticide;
xenobiotic
lamotrigine
[no description available]		2.25101,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
phorate
Phorate: A cholinesterase inhibitor that is used as an insecticide.. phosphatidylcholine O-34:2 : A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 34 carbons and 2 double bonds.		2.0510organic thiophosphate;
organothiophosphate insecticide		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		2.0310C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		2.0810adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		210amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
bisphenol a
4,4'-isopropylidene diphenol: stimulates proliferative responses and cytokine productions of murine spleen cells and thymus cells in vitro. bisphenol : By usage, the methylenediphenols, HOC6H4CH2C6H4OH, commonly p,p-methylenediphenol, and their substitution products (generally derived from condensation of two equivalent amounts of a phenol with an aldehyde or ketone). The term also includes analogues in the the methylene (or substituted methylene) group has been replaced by a heteroatom.. bisphenol A : A bisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups.		2.0610bisphenolendocrine disruptor;
environmental contaminant;
xenobiotic;
xenoestrogen
triethylamine
[no description available]		2.0310tertiary amine
4-tert-octylphenol
4-tert-octylphenol: structure given in first source		2.0610alkylbenzene
linuron
Linuron: A selective pre- and post-emergence herbicide. (From Merck Index, 11th ed). linuron : A member of the class of phenylureas that is N-methyl urea substituted by a methoxy group at position 1 and a 3,4-dichlorophenyl group at position 3.		2.1110dichlorobenzene;
phenylureas		agrochemical;
environmental contaminant;
herbicide;
xenobiotic
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		2.1110C-nitro compound;
imidazoles		antitubercular agent
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		2.5520dialdehydebiomarker
neutral red
Neutral Red: A vital dye used as an indicator and biological stain. Various adverse effects have been observed in biological systems.. neutral red : A hydrochloride obtained by combining the free base of neutral red with one equivalent of hydrochloric acid. Neutral red acts as a pH indicator, changing from red to yellow between pH 6.8 and 8.0.		2.1710hydrochlorideacid-base indicator;
dye;
two-colour indicator
silver
Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.		7.4820copper group element atom;
elemental silver		Escherichia coli metabolite
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		2.0310copper group element atom;
elemental gold
silver perchlorate
[no description available]		2.0510
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		2.1110C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
diflubenzuron
Diflubenzuron: An insect growth regulator which interferes with the formation of the insect cuticle. It is effective in the control of mosquitoes and flies.. diflubenzuron : A benzoylurea insecticide that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 4-chlorophenyl group, and a hydrogen attached to the other nitrogen is replaced bgy a 2,6-difluorobenzoyl group.		2.110benzoylurea insecticide;
monochlorobenzenes		insect sterilant
triflumuron
triflumuron: insect growth inhibitor		2.110aromatic ether;
benzoylurea insecticide;
monochlorobenzenes;
organofluorine compound
trioctyl phosphine oxide
[no description available]		2.0510
9,10-dicyanoanthracene
9,10-dicyanoanthracene: structure in first source. anthracene-9,10-dinitrile : An anthracenedinitrile carrying cyano groups at positions 9 and 10.		2.0310acene-9,10-dinitrile;
anthracenedinitrile
fluphenacur
fluphenacur: RN given refers to parent cpd		2.110aromatic ether;
benzoylurea insecticide;
dichlorobenzene;
N-acylurea;
organofluorine compound
teflubenzuron
teflubenzuron: effective against development of house fly larvae (Musca domestica). teflubenzuron : A N-acylurea that is N-carbamoyl-2,6-difluorobenzamide substituted by a 3,5-dichloro-2,4-difluorophenyl group at the terminal nitrogen atom.		2.110dichlorobenzene;
difluorobenzene;
N-acylurea		environmental contaminant;
insecticide;
xenobiotic
hexafluoron
hexafluoron: insect growth regulator against mosquito larva; the active agent in Sonet, a Russian product, is hexaflumuron. hexaflumuron : An N-acylurea that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 2,6-difluorobenzoyl group, while a hycrogen attached to the other nitorgen is replaced by a 3,5-dichloro-4-(1,1,2,2-tetrafluoroethoxy)phenyl group.		2.110aromatic ether;
benzoylurea insecticide;
dichlorobenzene;
N-acylurea;
organochlorine insecticide;
organofluorine insecticide
flufenoxuron
[no description available]		2.110(trifluoromethyl)benzenes;
benzoylurea insecticide;
difluorobenzene;
monochlorobenzenes;
monofluorobenzenes		mite growth regulator
n-acetylphenylalanine ethyl ester
N-acetylphenylalanine ethyl ester: RN given refers to (L)-isomer		210
ulipristal acetate
RTI 3021-012: progesterone receptor antagonist. ulipristal acetate : A 20-oxo steroid obtained by acetylation of the 17-hydroxy group of (11beta,17alpha)-17-acetyl-11-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17-ol (ulipristal). A selective progesterone receptor modulator, which is employed as an emergency contraceptive.		2.111020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester;
tertiary amino compound		contraceptive drug;
progesterone receptor modulator;
progestin
proline
Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.		2.110amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.3110cyclodextrin
1-butyl-3-methylimidazolium hexafluorophosphate
1-butyl-3-methylimidazolium hexafluorophosphate: structure in first source		8.1450
1-butyl-3-methylimidazolium tetrafluoroborate
[no description available]		2.9940
1-methyl-3-octylimidazolium chloride
1-methyl-3-octylimidazolium chloride: use as an ionic liquid solution. 3-methyl-1-octylimidazolium chloride : An organic chloride salt in which the cationic component is 3-methyl-1-octylimidazolium.		2.0510organic chloride salt
buclizine
1-octyl-3-methylimidazolium: structure in first source. 3-methyl-1-octylimidazolium : A 1-alkyl-3-methylimidazolium in which the alkyl substituent at C-1 is octyl.		2.59201-alkyl-3-methylimidazolium
1-hexadecyl-3-methylimidazolium chloride
1-hexadecyl-3-methylimidazolium chloride: structure in first source		2.0510
alpha-chymotrypsin
Chymotrypsin: A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side.		210
nifurtimox
Nifurtimox: A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.		2.1110nitrofuran antibiotic
phoxim
phoxim: structure		2.0510
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.5520aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
chlorophyll b
[no description available]		2.1110chlorophyllcofactor
1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide
1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide: structure in first source		2.0710
chlorophyll a
Chlorophyll: Porphyrin derivatives containing magnesium that act to convert light energy in photosynthetic organisms.. chlorophyll : A family of magnesium porphyrins, defined by the presence of a fifth ring beyond the four pyrrole-like rings. The rings can have various side chains which usually include a long phytol chain.		2.5320chlorophyll;
methyl ester		cofactor
chitosan
[no description available]		2.0810
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		2.1110ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
pyrethrins
[no description available]		2.3110
pheophytin a
pheophytin a: structure given in first source; RN given refers to (3S-(3alpha(2E,7S*,11S*),4beta,21beta))-isomer		2.5320
sildenafil citrate
Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.		2.0810citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
vardenafil dihydrochloride
Vardenafil Dihydrochloride: A piperazine derivative, PHOSPHODIESTERASE 5 INHIBITOR and VASODILATOR AGENT that is used as a UROLOGICAL AGENT in the treatment of ERECTILE DYSFUNCTION.		2.0810
methisosildenafil
methisosildenafil: synthetic analog in which the N-methylpiperazine moiety has been replaced with 2,6-dimethylpiperazine; structure in first source		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
American Trypanosomiasis
[description not available]		02.1110
Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.		02.1110
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0310